Author

Andreas Müller

Institution: Kantonsspital Winterthur

Observed institution: Kantonsspital Winterthur

ORCID: 0000-0003-4561-2628

Observed ORCID: 0000-0003-4561-2628

OpenAlex ID: A5122935569

Prevalence of symptomatic skeletal events (SSE) with reduced denosumab (Dmab) dose density (every 12 weeks versus every 4 weeks): A randomized phase III non-inferiority trial SAKK 96/12 REDUSE.

2026 · Roger Anton Fredy Von Moos, Andreas Müller, et al. · Journal of Clinical Oncology · 4

24-week home-based walking program in the early adjuvant setting in breast cancer patients who receive aromatase inhibitor endocrine therapy: lessons learned from the SAKK 95/17 WISE prospective, randomized, multicenter trial

2026 · Uwe Güth, Nicolette Hoefnagels, et al. · The Breast · 2

Trends in postmastectomy radiotherapy for early and locally advanced breast cancer in Switzerland: a population-based cross-sectional and longitudinal analysis

2026 · Marcel Blum, Sonja Marion Koch, et al. · Breast Cancer Research and Treatment · 1

Works count: 3

Citation count: 7

H-index: 2

I10-index: